Abstract | BACKGROUND: The aim of our study was to explore the anti-tumoral potential of the Nitric Oxide-Donating Non-Steroidal Anti-Inflammatory Drugs (NO- NSAID) NCX1102 ( nitrosulindac), on three human prostatic epithelial cell lines at varying degree of transformation (PNT1A, LNCaP, and PC3). METHODS: RESULTS:
Nitrosulindac but not sulindac exerted a cytotoxic effect on all cell lines and an anti-proliferative effect on LNCaP and PC3 cells only. Nitrosulindac differentially altered the cell cycle, induced mitotic arrest and displayed a pro-apoptotic activity in all cell lines. Finally, the polyamine pathway does not seem to be involved in the mechanism of nitrosulindac action. CONCLUSIONS:
|
Authors | Sandra Huguenin, Jocelyne Fleury-Feith, Laurence Kheuang, Marie-Claude Jaurand, Manlio Bolla, Jean-Pierre Riffaud, Dominique K Chopin, Francis Vacherot |
Journal | The Prostate
(Prostate)
Vol. 61
Issue 2
Pg. 132-41
(Oct 01 2004)
ISSN: 0270-4137 [Print] United States |
PMID | 15305336
(Publication Type: Journal Article)
|
Copyright | Copyright 2004 Wiley-Liss, Inc |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- nitrosulindac
- Sulindac
- Nitric Oxide
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(metabolism, pharmacology)
- Apoptosis
(drug effects)
- Cell Cycle
(drug effects)
- Cell Division
(drug effects)
- Cell Line
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Epithelial Cells
(drug effects)
- Humans
- Male
- Nitric Oxide
(metabolism)
- Prostate
(cytology)
- Prostatic Neoplasms
(drug therapy, prevention & control)
- Sulindac
(analogs & derivatives, metabolism, pharmacology)
|